AT 132

Drug Profile

AT 132

Alternative Names: AT-001 - Audentes Therapeutics/Genethon; AT-132

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Audentes Therapeutics; Genethon
  • Developer Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Congenital structural myopathies

Most Recent Events

  • 02 Aug 2017 Phase-I/II clinical trials in Congenital structural myopathies (In infants, In children) in USA (IV)
  • 26 Aug 2015 AT 132- receives Orphan Drug status for Congenital structural myopathies in European Union
  • 26 Aug 2015 AT 132- receives Orphan Drug status for Congenital structural myopathies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top